Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juvéderm Ultra 2
- Development stage
- Unknown
- Lead developer
- Allergan Aesthetics
- Modality
- Small Molecules
- Administration
- Intradermal
01
Overview
Juvéderm Ultra 2 is a cross-linked hyaluronic acid (HA)-based dermal filler developed by Allergan Aesthetics (a subsidiary of AbbVie). It is engineered using Vycross technology, which integrates low and high molecular weight HA chains to produce a smooth, cohesive gel that resists degradation. The formulation includes lidocaine to reduce pain during the injection process. Juvéderm Ultra 2 is specifically designed for injection into the superficial to middle dermis to treat fine to moderate facial wrinkles, enhance lip contours, and correct nasolabial folds. Its mechanism involves the restoration of volume and hydration by attracting water molecules within the extracellular matrix. In clinical settings, it has been investigated in Phase 4 studies for the treatment of glabellar frown lines, particularly in combination with botulinum toxin type A to assess the longevity of the filler's effects.
- Brand names
- Juvéderm Ultra 2
- Other names
- Juvederm Ultra 2
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on Juvéderm Ultra 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Juvéderm Ultra 2.